ClinicalTrials.gg
CompletedNCT01709500ODYSSEY FH IIUpdated Oct 28, 2015Results posted

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

A Phase 3 interventional study of LMT (atorvastatin, simvastatin, or rosuvastatin) and alirocumab in Heterozygous Familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.

Enrollment
11th of 33
249 · median 153
Started
2012
with 2 others
Phase 3
14 of 35
3 open now
Registered
16th of 35
by date

Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2012, is one of 14 in phase 3, and was the 16th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study alirocumab (REGN727/SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT).

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with heFH* who are not adequately controlled** with a maximally-tolerated daily dose*** of statin with or without other LMT, at a stable dose prior to the screening visit (week -2).

    *Diagnosis of heFH must be made either by genotyping or by clinical criteria. For those patients not genotyped, the clinical diagnosis may be based on either the Simon Broome criteria for definite FH (Appendix 1) or the WHO/Dutch Lipid Network criteria with a score of >8 points (Appendix 2).

    ** "Not adequately controlled" is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) at the screening visit (week -2) in patients with a history of documented CVD (Appendix 3), or LDL-C ≥100 mg/dL (2.59 mmol/L) at the screening visit (week -2) in patients without a history of documented CVD.

    *** "Maximally-tolerated dose" is defined as (any of the following are acceptable):

    • Rosuvastatin 20 mg or 40 mg daily
    • Atorvastatin 40 mg or 80 mg daily
    • Simvastatin 80 mg daily (if already on this dose for >1 year - see exclusion criterion #7)

    Note: Patients who are not able to be on any of the above statin doses should be treated with the dose of daily atorvastatin, rosuvastatin, or simvastatin which is considered appropriate for the patient, according to the investigator's judgment. Some examples of acceptable reasons for a patient taking a lower statin dose include, but are not limited to: adverse effects on higher doses, advanced age, low , regional practices, local prescribing information, concomitant medications, co-morbid conditions such as impaired glucose tolerance/impaired fasting glucose. The reason(s) will be documented in the case report form (CRF).

  2. Provide signed

Exclusion criteria

Exclusion Criteria:

  1. Patient without diagnosis of heFH made either by genotyping or by clinical criteria
  2. LDL-C \<70 mg/dL (\<1.81 mmol/L) at the screening visit (week-2) in patients with history of documented cardiovascular disease
  3. LDL-C \<100 mg/dL (\<2.59 mmol/L) at the screening visit (week -2) in patients without history of documented cardiovascular disease
  4. Not on a stable dose of LMT (including statin) for at least 4 weeks and/or fenofibrate for at least 6 weeks, as applicable, prior to the screening visit (week -2) and from screening to randomization
  5. Currently taking another statin than simvastatin, atorvastatin, or rosuvastatin
  6. Simvastatin, atorvastatin, or rosuvastatin is not taken daily or not taken at a registered dose
  7. Daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg (except for patients on simvastatin 80 mg for more than 1 year, who are eligible)
  8. Use of fibrates, other than fenofibrate within 6 weeks of the screening visit (week-2) or between screening and randomization visits
  9. Use of nutraceutical products or over-the-counter therapies that may affect lipids which have not been at a stable dose/amount for at least 4 weeks prior to the screening visit (week -2) or between screening and randomization visits
  10. Use of red yeast rice products within 4 weeks of the screening visit (week-2), or between screening and randomization visits
  11. Patient who has received plasmapheresis treatment within 2 months prior to the screening visit (week -2), or has plans to receive it during the study
  12. Recent (within 3 months prior to the screening visit [week -2] or between screening and randomization visits) MI, unstable angina leading to hospitalization, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), uncontrolled cardiac arrhythmia, stroke, (TIA), carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease

(The inclusion/exclusion criteria provided above is not intended to contain all considerations relevant to a participant's potential participation in this clinical trial).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Alirocumab 75 mg/up to 150 mg

    Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.

    Drug: LMT (atorvastatin, simvastatin, or rosuvastatin) · Drug: alirocumab

  • Placebo comparator
    Placebo

    Placebo matched to alirocumab SC injection for 78-week treatment duration.

    Drug: Placebo

Interventions

  • DrugLMT (atorvastatin, simvastatin, or rosuvastatin)
  • Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

    Also known as: REGN727, SAR236553

  • DrugPlacebo

    Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Adjusted Least- squares (LS) means and standard errors at Week 24 were obtained from a mixed -effect model with repeated measures (MMRM) to account for missing data. All available post -baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model.

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

    Time frame: From Baseline to Week 52

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment (ITT analysis).

    Time frame: From Baseline to Week 52

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

    Time frame: From Baseline to Week 52

  4. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  5. Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  6. Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  7. Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

    Time frame: From Baseline to Week 52

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  9. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 52

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post baseline data from Week 4 to Week 52 regardless of status on- or off treatment.

    Time frame: From Baseline to Week 52

  12. Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off treatment (ITT analysis).

    Time frame: From Baseline to Week 52

  13. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 52

  14. Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).

    Time frame: Up to week 52

  15. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 52

  16. Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis

    Adjusted percentages at Week 52 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).

    Time frame: Up to Week 52

  17. Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  18. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  19. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  20. Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  21. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  22. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  23. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

  24. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

    Time frame: From Baseline to Week 52

07

Results

Posted Oct 28, 2015

Participant flow

The study was conducted at 26 sites in 4 countries. Overall, 322 participants were screened between 28 Nov 2012 and 26 Apr 2013, 73 of whom were screen failures.

Participant flow — Overall Study
MilestoneAlirocumab 75 mg/up to 150 mgPlacebo
Started16782
Treated16781
Completed00
Not completed16782
Withdrew: Randomized but not treated01
Withdrew: Adverse event51
Withdrew: Poor compliance to protocol21
Withdrew: Other31
Withdrew: Related to imp administration10
Withdrew: Treatment ongoing15678

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Adjusted Least- squares (LS) means and standard errors at Week 24 were obtained from a mixed -effect model with repeated measures (MMRM) to account for missing data. All available post -baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis-48.7 ± 1.92.8 ± 2.8
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -51.4 · 95% CI -58.1 to -44.8
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis-49.4 ± 1.92.7 ± 2.7
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -52.2 · 95% CI -58.7 to -45.6
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment (ITT analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis-43.8 ± 1.84.6 ± 2.6
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -48.4 · 95% CI -54.7 to -42.2
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis-44.2 ± 1.84.6 ± 2.6
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -48.8 · 95% CI -55 to -42.5
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis-42.8 ± 1.4-3.5 ± 2
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -39.3 · 95% CI -44.1 to -34.5
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis-43.2 ± 1.4-3.5 ± 2
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -39.8 · 95% CI -44.5 to -35.1
SecondaryPercent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis-42.6 ± 1.83.1 ± 2.5
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -45.7 · 95% CI -51.8 to -39.7
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis-43.2 ± 1.73.1 ± 2.5
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -46.4 · 95% CI -52.3 to -40.4
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-30.6 ± 1.42.1 ± 1.9
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -32.8 · 95% CI -37.4 to -28.1
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis-35.4 ± 1.4-0.9 ± 2
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -34.5 · 95% CI -39.2 to -29.8
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-37.9 ± 1.74.1 ± 2.4
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -42 · 95% CI -47.8 to -36.2
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post baseline data from Week 4 to Week 52 regardless of status on- or off treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-26.6 ± 1.33.4 ± 1.9
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -29.9 · 95% CI -34.5 to -25.4Threshold for significance ≤ 0.05.
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off treatment (ITT analysis).

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis-50.3 ± 2.38.4 ± 3.3
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.05.) · Ls mean difference: -58.8 · 95% CI -66.8 to -50.8
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsAlirocumab 75 mg/up to 150 mgPlacebo
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis81.411.3
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 52.2 · 95% CI 20.9 to 130
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).

Time frame:
Up to week 52
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsAlirocumab 75 mg/up to 150 mgPlacebo
Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis82.111.6
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 53.3 · 95% CI 21.4 to 132.6
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsAlirocumab 75 mg/up to 150 mgPlacebo
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis68.21.2
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 239.7 · 95% CI 31.6 to 1820.3
SecondaryPercentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis

Adjusted percentages at Week 52 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection (on-treatment analysis).

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis
percentage of participantsAlirocumab 75 mg/up to 150 mgPlacebo
Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis68.81.3
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.05.) · Odds ratio (or): 240.6 · 95% CI 31.4 to 1841.7
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis-30.3 ± 1.8-10 ± 2.5
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -20.3 · 95% CI -26.4 to -14.2
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis6.0 ± 1.2-0.8 ± 1.6
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = = 0.0009 (Threshold for significance ≤ 0.05.) · Ls mean difference: 6.8 · 95% CI 2.8 to 10.7
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-10.4 ± 20.5 ± 2.8
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Robust · p = = 0.0012 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -10.9 · 95% CI -17.5 to -4.3
SecondaryPercent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis2.8 ± 0.9-1.6 ± 1.3
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = = 0.0062 (Threshold for significance ≤ 0.05.) · Ls mean difference: 4.4 · 95% CI 1.3 to 7.5
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis-24.7 ± 1.7-5.6 ± 2.5
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -19.1 · 95% CI -25 to -13.1
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis6.0 ± 1.0-0.8 ± 1.6
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = = 0.0147 (Threshold for significance ≤ 0.05.) · Ls mean difference: 4.3 · 95% CI 0.9 to 7.8
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis-8.1 ± 2.20.6 ± 3.1
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Regression, Robust · p = = 0.024 (Threshold for significance ≤ 0.05.) · Adjusted mean difference: -8.6 · 95% CI -16.1 to -1.1
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.

Time frame:
From Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changeAlirocumab 75 mg/up to 150 mgPlacebo
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis0.4 ± 0.9-1.9 ± 1.3
Statistical analysis
  • Alirocumab 75 mg/up to 150 mg vs Placebo · Mixed Models Analysis · p = = 0.1475 (Threshold for significance ≤ 0.05.) · Ls mean difference: 2.3 · 95% CI -0.8 to 5.5

Adverse events

Collected over From Baseline up to Week 78. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alirocumab 75 mg/up to 150 mg—10/167 (6%)65/167 (38.9%)
Placebo—7/81 (8.6%)35/81 (43.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAlirocumab 75 mg/up to 150 mgPlacebo
Acute coronary syndromeCardiac disorders0/1671/81
Angina unstableCardiac disorders0/1671/81
Cardiogenic shockCardiac disorders0/1671/81
Myocardial infarctionCardiac disorders0/1671/81
Gastrointestinal haemorrhageGastrointestinal disorders0/1671/81
Non-Cardiac chest painGeneral disorders0/1671/81
EndocarditisInfections and infestations0/1671/81
Lower respiratory tract infectionInfections and infestations0/1671/81
Viral infectionInfections and infestations0/1671/81
Femoral neck fractureInjury, poisoning and procedural complications0/1671/81
Most frequent other events
Most frequent other events
EventAlirocumab 75 mg/up to 150 mgPlacebo
NasopharyngitisInfections and infestations18/16716/81
InfluenzaInfections and infestations24/1676/81
Injection site reactionGeneral disorders18/1676/81
HeadacheNervous system disorders14/1677/81
MyalgiaMusculoskeletal and connective tissue disorders10/1675/81
DiarrhoeaGastrointestinal disorders9/1671/81

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alirocumab 75 mg/up to 150 mgPlaceboTotal
Mean53.2 ± 12.9353.2 ± 12.5553.2 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Alirocumab 75 mg/up to 150 mgPlaceboTotal
Female8137118
Male8645131
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Alirocumab 75 mg/up to 150 mgPlaceboTotal
Mean3.485 ± 1.0653.471 ± 1.0713.480 ± 1.065
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Alirocumab 75 mg/up to 150 mgPlaceboTotal
Mean134.6 ± 41.1134.0 ± 41.4134.4 ± 41.1
08

Study locations

26 sites
  • Hradec Kralove, Czech Republic
  • Praha 2, Czech Republic
  • Praha 5, Czech Republic
  • Praha 8, Czech Republic
  • Trutnov, Czech Republic
  • Vyskov, Czech Republic
  • Alkmaar, Netherlands
  • Amsterdam, Netherlands
  • Apeldoorn, Netherlands
  • Enschede, Netherlands
  • Goes, Netherlands
  • Groningen, Netherlands
  • Hoogeveen, Netherlands
  • Hoorn, Netherlands
  • Rotterdam, Netherlands
  • Sittard- Geleen, Netherlands
  • Utrecht (2 locations), Netherlands
  • Venlo, Netherlands
  • Waalwijk, Netherlands
  • Oslo, Norway
  • Cardiff, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Middlesex, United Kingdom
  • Newcastle upon Tyne, United Kingdom
  • West Bromwich, United Kingdom
09

References and documents

Publications

  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4. Erratum In: J Clin Lipidol. 2020 Sep - Oct;14(5):742. doi: 10.1016/j.jacl.2020.09.010. PubMed 28964736 ↗
  • Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Jan-Feb;11(1):195-203.e4. doi: 10.1016/j.jacl.2016.12.004. Epub 2016 Dec 28. PubMed 28391886 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
  • Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1. PubMed 26330422 ↗
  • Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9. doi: 10.1007/s10557-014-6523-z. PubMed 24842558 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of May 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2012
First posted
Oct 18, 2012
Start
Dec 2012
Primary completionActual
May 2014
CompletionActual
Jan 2015
Results delay requested
Jan 24, 2015
Results first posted
Oct 28, 2015
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01709500
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Dec 2012
Primary completion
May 2014
Completion
Jan 2015
Results posted
Oct 28, 2015
Last update
Oct 28, 2015

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion